IMV

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Wednesday, March 6, 2024

VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 6, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Technology Corp. Granted Voluntary Management Cease Trade Order

Retrieved on: 
Friday, March 8, 2024

VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").

Key Points: 
  • VANCOUVER, BC, March 8, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (the "Company") today announced that the Ontario Securities Commission (the "OSC"), as the Company's principal regulator, on February 29, 2024, granted the Company's previously announced application for the imposition of a management cease trade order under National Policy 12-203 – Management Cease Trade Orders ("NP 12-203").
  • The management cease trade order is to remain in place until two full business days after the Company files the Required Reports and restricts all trading by James Passin, director, CEO and CFO of the Company in securities of the Company.
  • The Company applied for a management cease trade order as an alternative to the imposition by the OSC of a full cease trade order.
  • The management cease trade order prevents the officers and/or directors named in the order from trading in the Company's securities but does not affect the ability of other shareholders, including the public, to trade in securities of the Company.

BioVaxys Announces Allowance of DPX-Related Patent for Japan and Filing of Additional International Patent Applications

Retrieved on: 
Tuesday, March 5, 2024

This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.

Key Points: 
  • This Patent was part of the extensive Intellectual Property portfolio recently acquired by BioVaxys from the former IMV, Inc.
  • This Patent has already been issued in the US, and is currently pending in the EU.
  • BioVaxys also is pleased to announce it filed an international patent application through the Patent Cooperation Treaty ("PCT") from two pending patent applications in the US related to methods of formulating DPX™ compositions that comprise both a lipid-based adjuvant (i.e.
  • The PCT is a patent treaty with more than 150 member countries, makes it possible to seek patent protection for an invention simultaneously in a large number of countries by filing a single "international" patent application instead of filing several separate national or regional patent applications.

BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.

Retrieved on: 
Wednesday, February 21, 2024

At the closing, BioVaxys delivered to HIMV a one-time payment of both US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of CAD$0.067.

Key Points: 
  • At the closing, BioVaxys delivered to HIMV a one-time payment of both US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of CAD$0.067.
  • With the transaction now complete, BioVaxys is working on integrating the acquired assets into the Company.
  • BioVaxys President and Chief Operating Officer Kenneth Kovan stated "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases.
  • We will be identifying target partners where our solutions can address specific needs or gaps, making BioVaxys an attractive 'go-to' partner for targeted immunotherapies."

BIOVAXYS COMPLETES THE ACQUISITION OF ALL INTELLECTUAL PROPERTY, IMMUNOTHERAPEUTICS PLATFORM TECHNOLOGY, AND CLINICAL STAGE ASSETS OF THE FORMER IMV INC.

Retrieved on: 
Wednesday, February 21, 2024

At the closing, BioVaxys delivered to HIMV a one-time payment of both US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of CAD$0.067.

Key Points: 
  • At the closing, BioVaxys delivered to HIMV a one-time payment of both US$750,000 in cash and 5,034,701 common shares of BioVaxys at a deemed price of CAD$0.067.
  • With the transaction now complete, BioVaxys is working on integrating the acquired assets into the Company.
  • BioVaxys President and Chief Operating Officer Kenneth Kovan stated "We now have massive opportunities in oncology, infectious disease, allergy desensitization, and autoimmune diseases.
  • We will be identifying target partners where our solutions can address specific needs or gaps, making BioVaxys an attractive 'go-to' partner for targeted immunotherapies."

CalciMedica Announces FDA Clearance of IND Application for Phase 2 Trial of Auxora™ for the Treatment of Severe Acute Kidney Injury

Retrieved on: 
Tuesday, February 13, 2024

LA JOLLA, Calif., Feb. 13, 2024 /PRNewswire/ -- CalciMedica, Inc. (CalciMedica or the Company) (Nasdaq: CALC), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic diseases, today announced the clearance of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) for the Company's lead product candidate, Auxora™, a potent and selective small molecule inhibitor of Orai1-containing CRAC channels, to be evaluated in a Phase 2 trial in acute kidney injury (AKI) with associated acute hypoxemic respiratory failure (AHRF). CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.

Key Points: 
  • CalciMedica expects to initiate the trial, named KOURAGE, in the first half of 2024 and data expected in 2025.
  • "Through KOURAGE, we aim to determine how Auxora can benefit patients with severe AKI and potentially reduce the high mortality rate associated with this disease."
  • AKI is classified as stages 1, 2 and 3 depending on the degree of kidney injury.
  • A single dose of Auxora after IRI increased GFR by 61% and decreased mononuclear (inflammatory) cell infiltration by 30%.

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Retrieved on: 
Monday, February 12, 2024

HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.

Key Points: 
  • HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
  • The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers.
  • These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function.
  • Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

Retrieved on: 
Monday, February 12, 2024

HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.

Key Points: 
  • HIMV will also be entitled to appoint an observer to BioVaxys's Board of Directors.
  • The DPX™ antigen delivery platform acquired by BioVaxys is designed to stimulate a specific, coordinated and persistent anti-tumor immune response, improving the lives of patients with solid or hematological cancers.
  • These elements foster maturation of antigen presenting cells as well as robust activation of CD8 T cell effector and memory function.
  • Findings showed clinical benefit to patients with recurrent ovarian cancer, regardless of platinum sensitivity or BRCA mutational status.

Industrial Metaverse Spend to Reach US$6.3 Billion by 2030 As Immersive Engineering Use Cases Take Hold

Retrieved on: 
Thursday, February 8, 2024

NEW YORK, Feb. 8, 2024 /PRNewswire/ --The industrial metaverse (IMV) is set to greatly enhance manufacturing engineering, training, safety, and production.

Key Points: 
  • NEW YORK, Feb. 8, 2024 /PRNewswire/ --The industrial metaverse (IMV) is set to greatly enhance manufacturing engineering, training, safety, and production.
  • According to a new report from global technology intelligence firm ABI Research, spending on industrial metaverse solutions and services will grow at 22.8% to reach US$6.3 billion by 2030 as immersive and collaborative capabilities come to the forefront of industry 4.0 software development efforts.
  • "The dream to enable full factory metaverse experiences is far from realized, but the work has begun," Martin concludes.
  • The broader environment is well-suited to partnerships that ease points of integration and enable marketplaces in the long run."